Cargando…
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
INTRODUCTION: The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and...
Ejemplares similares
-
Neurofilaments contribution in clinic: state of the art
por: Delaby, Constance, et al.
Publicado: (2022) -
A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
por: Lehmann, Sylvain, et al.
Publicado: (2014) -
Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015) -
Central Nervous System and Peripheral Inflammatory Processes in Alzheimer’s Disease: Biomarker Profiling Approach
por: Delaby, Constance, et al.
Publicado: (2015) -
Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Dulewicz, Maciej, et al.
Publicado: (2020)